Advertisement
Staged pivotal noninferiority study is comparing BrioVAD with HeartMate 3
Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor
Yet 21.4% of tested individuals had Lp(a) elevation
While results were negative for metformin, lifestyle counseling showed surprising promise
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Launch of the tool promises to reshape quality assessment across the specialty
AHA scientific statement outlines models for high-intensity staffing, specialized expertise and more
5% of flagged ECGs in real-world study were from patients with previously undiagnosed HCM
Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose
Phase 2b trial of aldosterone synthase inhibitor also finds no benefit from dose escalation
Patient series and bench validation support efficacy and safety of CLEVE procedure
Advertisement
Advertisement